WO2004053051A2 - Gelatine-based materials as swabs - Google Patents
Gelatine-based materials as swabs Download PDFInfo
- Publication number
- WO2004053051A2 WO2004053051A2 PCT/DK2003/000855 DK0300855W WO2004053051A2 WO 2004053051 A2 WO2004053051 A2 WO 2004053051A2 DK 0300855 W DK0300855 W DK 0300855W WO 2004053051 A2 WO2004053051 A2 WO 2004053051A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gelatine
- swab
- collagen
- sponge
- target
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/02—Devices for withdrawing samples
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/02—Instruments for taking cell samples or for biopsy
- A61B10/0291—Instruments for taking cell samples or for biopsy for uterus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/38—Swabs having a stick-type handle, e.g. cotton tips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/02—Devices for withdrawing samples
- G01N2001/028—Sampling from a surface, swabbing, vaporising
Definitions
- a gelatine or collagen-based material is used in the collection of targets such as microbiological cells, mammalian cells, nucleotides and other chemical and biological molecules from an array of collection media.
- Gelatine-based sponges have been used as haemostatic agents in surgical procedures.
- EP 0 702 081 discloses a matrix for tissue culturing comprising two kinds of sponges.
- US 5,462, 860 discloses a culture medium for rapid growth and detection of microbes.
- a gelatine-based sponge has been found to be useful in the collection of a variety of materials, such as microbes and mammalian cells, but also mammalian tissue and various molecules, including nucleotides, from an array of collection media.
- the sponge can be used for instance for sampling and culturing purposes.
- the present inventors have surprisingly found that the sponge has a dramatically higher recovery level of the sampled material than conventional methods.
- the target material bound to the sponge can be transferred from the sponge to another medium by an array of methods.
- a first object of the invention relates to a device comprising a device for sampling or collecting comprising i) a swab comprising gelatine or collagen; and ii) a support fixed to said swab.
- the device or the gelatine-based sponge may be used for an array of applications related to the high recovery of targets from the sponge.
- a further object of the invention relates to the use of a gelatine-based sponge for collection of a target from a collection medium comprising making contact between the gelatine-based sponge and the medium.
- an object of the invention relates to a method of lowering the amount of a target in a sample area comprising making contact between a gelatine-based sponge and at least a portion of said sample area, such that the target adheres to the sponge.
- An important and further utilisation of the surprising properties of the sponge relate to a method of qualitatively or quantitatively sampling an area for content of a target comprising the use of a gelatine-based sponge and the steps of i) wet sampling using the gelatine-based sponge; and/or ii) dry-sampling using the gelatine-based sponge.
- a similarly important aspect of the invention relates to a method for culturing micro-organisms or mammalian cells comprising adhering the cells to a gelatine-based sponge and culturing the cells in a growth medium.
- the invention provides a swab which has a high recovery of a target from a sample and furthermore a second high recovery when transferring from the swab to a medium for analysis.
- a target refers to any species which binds to the gelatine-based sponge of the invention.
- a collection medium refers to any medium from which said targets may be collected.
- transfer medium is intended to mean a medium to which the collected target is transferred.
- recovery is intended to mean the overall recovery yield of a target from a collection medium to transfer medium.
- recovery comprises i) the collection yield of a target to the collagen-based sponge of the present invention, as well as ii) the transfer yield from the collagen-based sponge to a transfer medium.
- a first transfer medium is, in the present context, considered to be a medium used in the collection of a target from the sponge. Suitable examples of a first transfer medium include an enzymatic solution, or a suitable washing agent to mechanically or chemically remove the target from the sponge into the medium, such as a liquid medium.
- a second transfer medium is considered to be represented by a second medium into which the first medium or the sample from the first medium, which includes the collected target, is transferred.
- a micro-organism is considered to be any organism selected from the group consisting of bacteria, bacterial spores, archea, yeast and fungi.
- a dispersion agent is, in the present context, considered to be any liquid agent into which targets may be dispersed following collection.
- a neutral diluent is considered to be a liquid which is neutral in the context of the assay process, i.e. it does not interfere with the diagnostic assay being performed.
- a neutral diluent is not necessarily, but can be, a diluent with neutral pH.
- Water, aqueous buffer solutions are suitable examples of neutral diluents.
- Ringer's solution refers to an aqueous solution comprising distilled water and sodium chloride, potassium chloride, and calcium chloride at roughly the same concentrations as their occurrence in body fluids.
- a “semi-solid surface” is a surface which is not strictly solid in nature, such as mammalian tissue or any other natural and/or synthetic tissue. Suitable examples of semi-solid surfaces are mammalian skin or other surfaces covered by connective tissue, such as surfaces of mammalian organs.
- a “detergent” can be any natural or synthetic, organic or inorganic, compound or a mixture of compound used for cleaning purposes, such as for the removal of impurities or contaminants from a surface.
- handle in the present context is to be considered to relate to any device that can be used for gripping, and should not be construed to be limited to devices specially designed to act as a handle.
- a stick attached to the gelatine-based sponge of the invention can thus be used to handle the sponge, and is therefore considered to represent a handle.
- a tweezer or tong which only temporarily connect to the sponge, is to be considered a handle.
- a swab is in the present context considered to be any material used for applying or removing material from an area or a surface. Swabbing refers to the method of applying or removing material from an area or surface using said swabs.
- the present invention relates to gelatine-based sponges and their properties with respect to binding of targets, such as micro-organisms and mammalian cells, as well as molecular species such as nucleotides, which are suitable for binding to the gelatine-based sponges.
- targets such as micro-organisms and mammalian cells
- molecular species such as nucleotides
- the binding properties of the aforementioned targets are useful for the collection of said targets from various media. Once the target is collected, it may be optionally be released from the sponge by mechanical, enzymatic, or chemical processes.
- the target is typically selected from the group consisting of a virus, a micro-organism, a mammalian cell and an organic molecule.
- the organic molecule is selected from the group consisting of a nucleotide, a nucleic acid, protein or a detergent.
- the nucleotide is a purine- or a pyrimidine-containing nucleotide, preferably ATP.
- the micro-organism is selected from the group consisting of bacteria, archea, bacterial spores, yeast and fungi.
- the mammalian cell may be selected from the group consisting of cells from blood plasma, leukocytes, erythrocytes, thrombocytes, but also other mammalian cells such as skin cells or any other type of mammalian cells that may be useful to collect for various diagnostic and/or cleaning purposes.
- the high recovery rate, resulting from the high collection yield of a target to the swab of the present invention, and/or the subsequent high transfer yield from the swab to a transfer medium requires, according to the present invention, i) a swab comprising gelatine or collagen.
- the swab is typically fixed onto a handle or support
- the swab may be selected from the group consisting of a gelatine-based sponge, collagen-based sponge, microfibrillar gelatine or microfibrillar collagen.
- the swab is a gelatine-based sponge or collagen-based sponge, more preferably a gelatine-based sponge.
- the gelatine-based sponge or collagen-based sponge material is preferentially comprised of at least 50% gelatine or collagen, respectively, such as at least 60%, such as at least 70%, typically at least 75%, preferably at least 80%, more preferably at least 85%, such as at least 90%, suitably at least 95%, most preferably selected from at least 96%, 97%, 98%, 99% gelatine or collagen, respectively, based on the dried weight of the sponge.
- the swab is a gelatine sponge or a collagen sponge, more preferably a gelatine sponge. That is to say that the swab itself is a sponge, typically comprising at least 95%, most preferably selected from at least 96%, 97%, 98%, 99% gelatine or collagen, respectively, based on the dried weight of the sponge.
- gelatine-based sponge or collagen-based sponge are characterised by their physical properties, which in particular may be described by the gelatine or collagen composition, pore size, reconfirmation rate, water absorption and digestibility of the sponge.
- the pore size of the sponge is considered to influence, at least in part, the ability of the sponge is collect and transfer the targets of the invention. Moreover, the pore size influences the density of the sponge, and also has an effect on its physical characteristics, such as reconfirmation rates and water absorption.
- the high recovery may be, in part, due an appropriate degree of roughness imparted by the surface of the swab, allow collection of the samples onto the surface of the swab of the invention.
- the physical properties imparted by the chemical nature of the collagen or gelatine comprised in the swab may also, in part, by an adhesion mechanism, contribute to the high recovery rate.
- pore size imparts, in part, an improvement to the high initial recovery.
- the gelatine or collagen in the gelatine-based sponge, collagen-based sponge, microfibrillar gelatine and micorfibrallar collagen will form or have pores with an average pore size of about 10 nm to about 2 mm.
- high recovery from the collection medium may be imparted by a form of capillary action into the swab.
- At least 10% of the pores may have a pore size of less 1000 nm, such as less than 800 nm, such as less than 500 nm, such as less than 400 nm.
- at least 10% of the pores may have a pore size of less than 100 ⁇ m, such as less than 80 ⁇ m, such as less than 50 ⁇ m, such as less than 10 ⁇ m.
- at least 10% of the pores may have a pore size of less than 1000 ⁇ m, such as less than 800 ⁇ m, such as less than 500 ⁇ m, such as less than 100 ⁇ m, such as less than 50 ⁇ m. It is within the meets and bounds of the skilled person to tailor the gelatine or collagen to a desired pore size and within the meets and bounds of the skilled person to select the pore size in accordance with the target.
- the gelatine or collagen of the gelatine-based or collagen- based sponge is of porcine origin. It is envisaged that the invention may be adapted to include gelatine with other origins, such as gelatine of bovine, or any other mammal, including marine mammal, fish or crayfish or vegetable origin, and including gelatine of any other origin, such as of gelatine of organic origin, or synthetic or semi-synthetic origin.
- Reconfirmation rates represent a measure of the elasticity of the gelatine-based or collagen- based sponge.
- the gelatine-based sponge has a reconfirmation rate of no more than 10 seconds, and typically no more than 5 seconds.
- the reconfirmation rate is typically determined by a method based on the rate at which the sponge regains its original size and shape, as described in Example 1.
- the gelatine-based sponge of the invention typically has a water absorption capacity which is in the range of at least 30g/g and more typically at least 40g/g, as determined in Example 3. It is however envisaged that the water absorption capacity of sponges based on gelatine from various sources may be in a wider range of at least 5g/g, such as at least lOg/g or at least 20g/g. The determination of water absorption is typically performed according to USP standards.
- the swab is a natural or synthetic material, such as an absorbent material comprising gelatine particles or collagen particles, preferably gelatine particles.
- the natural or synthetic absorbent material is essentially any material which within it or upon its surface can contain loosely bound or fixed, gelatine or cartilage particles.
- the gelatine or collagen particles may be entrapped by the loose or tight weave or matrix of the material or by a adhesive substance.
- the particles may have a particle size in the range of about 1 ⁇ m to about 2 mm, typically from about 5 ⁇ m to about 1 mm, such as from about 5 ⁇ m to about 0.5 mm, more typically about 5 ⁇ m to about 0.25 mm, preferably about 10 ⁇ m to about 0.25 mm, such as about 10 ⁇ m to about 0.1 mm.
- the swab has a content of gelatine particles or collagen particles, preferably gelatine particles, constituting from 1-95% wt/wt based upon the combined dry weight of the swab and the particles, such as 2-90%, typically 5-90%.
- the weight content will depend upon the nature of the natural or synthetic material.
- the swab is intended for use on an array of surfaces and other collection medium. Depending upon the use and collection medium, whether it be industrial machinery, walls, table tops, air vents to use in equipment in conventional or micro-scale laboratories, the size of the swab will vary. Typically, the swab is of the size in the range of about 1 cm x 1 cm to about 15 cm x 15 cm. It may be of any shape, depending on its use. Particular interesting is the use of collagen- based sponges or gelatine-based sponges since these are highly compressible and can be forced or squeezed into all crevices and holes.
- a further aspect of the invention is directed to a kit comprising i) a swab comprising gelatine or collagen; and ii) an agent selected from the group consisting of a neutral diluent, an antimicrobial agent and a dispersion agent.
- the swab may be as described above.
- the agent selected from the group consisting of a neutral diluent, an anti-microbial agent and a dispersion agent is present in order to assist in the collection or sampling of the target.
- a further aspect of the invention relates to the use of a device or kit as desribed herein for collection of a target from a collection medium comprising making contact between the swab and the target.
- the swab may be used for sampling for the presence of micro-organisms from a sample, such as from a surface.
- the micro-organism can be transferred from the swab by the methods of the invention.
- the thus collected micro-organisms may optionally be furthermore cultivated, which may find uses for specific purposes such as detailed characterization of said micro-organism.
- the swab may be used for quantitative removal of micro-organisms from a sample, such as a surface.
- anti-microbial or disinfecting agents may optionally be suitably incorporated into the swab.
- the swab may be adapted for use in collecting other types of cells in addition to micro-organisms, such as mammalian cells.
- Such an embodiment may be realised by, e.g. collection from mammalian surfaces, such as from mammalian skin or the surface of any mammalian organ.
- the swab may be adapted for internal use, such as during surgical operations on a mammal, and may in such embodiments be used to collect targets from wounds or from internal organs of a mammal, as well as surgical equipment and specialised furniture, walls or floors in a health clinic or a hospital, such as in surgical rooms, or in any other facility used to conduct or perform surgical procedures.
- the gelatine-based sponge binds certain molecules, such as purine- or pyrimidine-based nucleotides or nucleic acids, preferentially ATP, in a reversible fashion.
- This finding may find a useful application in that bacterial numbers have been estimated in foods by measuring the amount of bacterial adenosine triphosphate (ATP).
- ATP bacterial adenosine triphosphate
- the swab may more generally be adapted to collect a variety of molecular species, and thus the swab may find general use for collection of certain molecules.
- such molecules are purine- or pyrimidine-based nucleotides, such as ATP.
- such molecules are nucleic acids.
- the molecules are detergents, which may conveniently be collected from a sample, such as a surface.
- detergents can be any natural or synthetic, organic or inorganic, compound or a mixture of compound used for cleaning purposes, such as for the removal of impurities or contaminants from a surface.
- the swab may be adapted to collect a mixture of micro-organisms, mammalian cells and/or molecules simultaneously from a sample.
- it may be useful to configure the gelatine-based sponge such that one particular type of target is collected.
- the swab is adapted so that it comes into contact with or is attached to a support.
- a support can be that of providing a way of handling the swab without touching the sponge material itself, and thus avoiding contamination. This may be especially useful for embodiments in which the sponge is ideally pre-sterilized, i.e. in embodiments for the collection or analysis of micro-organisms or mammalian cells.
- a support may also facilitate the use of the swab, and allow convenient collection of targets from various samples.
- a support can furthermore be invaluable for the collection of targets from samples that may be difficult to reach or for other applications in which the swab is difficult to manipulate without a support.
- the support may be made of any suitable material for the particular use such as wood, natural 5 or synthetic polymeric material, including plastics and rubber materials, or any other organic or inorganic material suitable for the particular embodiment.
- the support may be of a wide variety, such as conveniently in the form of a handle.
- the handle may be short, such as in the range of about 1 cm to about 30 cm, such as about 3 cm to about
- a handle may suitably be considerably larger, such as in the range of about 30 cm to several meters in length.
- the handle may be of any shape convenient for the particular embodiment, but is typically elongated, optionally bent, with the gelatine-based sponge attached at one end of the handle, while the other end of the handle is used for gripping and otherwise applying the gelatine-based
- the gelatine-based sponge has an oval or otherwise elongated shaped sponge positioned at the end of a stick, which serves the function of a handle.
- the sponge is 20 attached to a solid support, such as a circular or rectangular support, which in turn is positioned on the end of a handle or stick.
- the swab may be adapted to be attached to a support in the form of a stick or handle in multiple different embodiments, suitably adapted for any given use of the gelatine-based sponge.
- the support is optionally in the form of a coating.
- the coating may be comprised of any suitable material, e.g. polymeric material or plastic material, or any other material suitably used to provide a coating.
- the coating is applied to one side of a swab of the invention which has been adapted to be in a flat shape.
- the support is a solid material which has a suitably adapted shape, such as the shape of a disc, cube, sphere or a block.
- the gelatine-based sponge is preferably attached to one side of the support, but may be attached to several or ail surfaces of the support in preferred embodiments.
- the swab is of a cubical shape may be particularly useful is an embodiment for collection of liquid samples or collection from surfaces comprising a liquid coating.
- the swab may suitably be attached to a support, which may optionally be in the shape of a handle, or suitably attached to a stick or a handle.
- the swab may be attached to the support by any conventional method known to those skilled in the art. The nature of such embodiments will depend on the particular shape of the embodiment and its intended use.
- the support may be in the form of a porous container, such as a crucible or otherwise suitable material shaped such that it encloses the swab while allowing liquid and targets to pass through the enclosing material.
- the encased gelatine-based sponge can be used to collect samples from a liquid. Such collection may suitably be performed by immersing the encased sponge into the liquid medium, thus allowing targets in the medium to come into contact with and bind to the gelatine-based sponge.
- gaseous targets may be any molecular species, which is gaseous at the temperature applied during collection, or is a liquid or a solid compound which has a vapour pressure high enough so that the target may be collected.
- a gaseous target is in this context considered to include targets which are solid in nature, including micro-organisms and mammalian cells, but either are trapped in liquid droplets or microdroplets or form particles that may be carried by gases, such as ambient atmosphere.
- gelatine powder or collagen powder may be applied directly to a sample for collection of targets, such as when the sample is or found within a liquid or fluid.
- the gelatine powder may in such embodiments be recovered by filtration, centrifugation or by other means known in the art.
- the gelatine powder may also be enclosed by a crucible or other suitable material shaped such that it encloses the powder, while allowing liquid and targets to pass through the enclosing material.
- a crucible or other suitable material shaped such that it encloses the powder, while allowing liquid and targets to pass through the enclosing material.
- Such embodiments may in particular be useful for collection from liquid media.
- the enclosing material is permeable to gaseous targets, and the collection of targets is realised by placing the encased powdered gelatine material in an environment containing said gaseous targets.
- Methods used for collecting targets from a surface using the swab of the present invention include techniques such as swab techniques and count-tact techniques.
- Swab techniques involve in principle a mechanical swiping or swabbing of a target, such as a surface, and are well known to those skilled in the art.
- Count-tact techniques involve the use of a specially designed instrument, as disclosed in Example 6.
- the gelatine-based sponge is used to collect targets from a sample.
- the target may be selected from the group comprising a micro-organism, mammalian cell, but may also be mammalian tissue, or alternatively a molecular species, such as a nucleic acid or a purine- or pyrimidine-based nucleotide, preferentially ATP.
- the micro-organism may be selected from the group consisting of bacteria, archea, bacterial spores, yeast, or fungus.
- the mammalian cell can be of any mammalian cell type, but may in particular be selected from the group consisting of cells from blood plasma, leukocytes, erythrocytes, thrombocytes, epithelial cells, skin cells or any other mammalian cell type that may be useful to collect for various diagnostic and/or cleaning purposes.
- targets are collected from a surface using a combination of wet- sampling and dry-sampling.
- wet-sampling is considered to comprise the use of a gelatine-based sponge of the invention, which optionally has been attached to a support and has been pre-wetted with a suitable neutral diluent or a dispersing agent.
- a suitable neutral diluent or a dispersing agent serves the purpose of facilitating the recovery of the targets from the surface, while not interfering with the assay.
- the diluent and dispersion agents may be any suitable aqueous solution, optionally including salts or other agents not toxic or otherwise chemically or biologically harmful for the targets to be collected, such as saline, saline peptone, buffered saline peptone, Ringer solution and an organic or inorganic buffer, optionally containing inorganic salts.
- the diluent or dispersion agent may also optionally contain growth media suitable for the micro-organism or mammalian cell type being collected, for assays directed towards such targets.
- the sponge may also optionally be presterilized.
- Collection of targets is realized by swiping the surface with at least one such pre-wetted sponge, followed by swiping of said surface with at least one dry gelatine-based sponge.
- the purpose of the dry swiping is to recover as much as possible of remaining liquid and target from the surface.
- Collection of targets may, in other embodiments, be realised by wet-sampling or dry-sampling alone.
- the choice of method to use will vary depending on the sample type to be assayed and the target type to be collected.
- Targets including micro-organisms, mammalian cells and/or molecules collected in the swab are typically transferred from the swab. Transfer of such collected targets comprises removing or unbinding such targets from the sponge into a suitable medium. In a preferred embodiment, this is accomplished by placing the gelatine-based sponge in a medium comprising a solution capable of digesting the gelatine-based sponge. Digestion of the sponge may be realized by chemical and/or enzymatic methods, preferably using enzymes such as proteases, more preferably using proteases such as alcalase or pepsin. Digestion by chemical means may comprise using mineral or carboxylic acids, or bases, in appropriate concentration not to denature the target.
- digestion comprises using a mixture of at least one enzyme, and may optionally include a mineral acid or a base, and optionally inorganic salts as well as organic or inorganic buffering agents.
- the temperature suitable for recovery of targets from the sponge will be highly dependent on the method used. In embodiments wherein transfer is realised using enzymes, the experimental temperature will be adjusted so as to maximise the efficiency of digestion for the particular enzyme in the context of the composition of the digestion medium employed.
- transfer of targets from the gelatine-based sponge of the invention may be realised by any technique known in the art which releases said target from the sponge. Thus, this may occur by changes in conditions such as pH or temperature, or by adding salts, chaotrophic agents or organic solvents. Transfer from the sponge may also optionally include mechanical action, such as that generated by rubbing or shaking the sponge, or by other mechanical means facilitating the unbinding of targets from the sponge. Transfer from the sponge may furthermore be realized by washing of a target from the gelatine-based sponge.
- preferred embodiments of the invention will include digestion methods for releasing micro-organisms and/or mammalian cells from the sponge, since micro-organisms and mammalian cells are in general sensitive to changes in conditions.
- digestion methods for releasing micro-organisms and/or mammalian cells from the sponge since micro-organisms and mammalian cells are in general sensitive to changes in conditions.
- Recovery of bound molecules to the sponge may be accomplished by any of the aforementioned techniques, depending on any given embodiment of the invention and the type of molecule bound.
- Micro-organisms or mammalian cells recovered from the gelatine-based sponge may optionally be further isolated using membrane filtration, wherein the membrane filter has properties such that it allows solvent and small molecules to pass through the filter, while whole cells and micro-organisms do not.
- a filter has a pore size of less than 1 ⁇ m, such as less than 0.8 ⁇ m, such as less than 0.6 ⁇ m, more typically less than 0.45 ⁇ m, such as less than 0.2 ⁇ m.
- the gelatine-based sponge is used to disinfect a sample, such as a surface.
- the combined action of the sponge which acts to remove targets, in this case micro-organisms and/or mammalian cells, from a sample, and optionally an anti-microbial or a disinfecting agent, facilitates the effective removal of said micro-organisms or mammalian cells from the sample, thus rendering it sterile.
- the sponge is in such embodiments preferably sterilised by methods known in the art, such as by heat and/or radiation, and optionally pre-treated with an anti-microbial or disinfecting agent.
- Such an agent is preferably a liquid, such as an alcohol, an aqueous solution comprising an alcohol or other liquid agent which kills micro-organisms or mammalian cells, but may be any compound which facilitates the sterilization procedure.
- a liquid such as an alcohol, an aqueous solution comprising an alcohol or other liquid agent which kills micro-organisms or mammalian cells, but may be any compound which facilitates the sterilization procedure.
- Embodiments for sterilization of samples may be realized by packaging individual gelatine-based sponges, optionally attached to a support and optionally pretreated with a sterilizing agent, individually into sealed packages, which are ideally intended for single use.
- viable micro-organisms or mammalian cells which have been trapped on the gelatine-based sponge can be cultured.
- Culturing in general requires contacting a micro-organism or mammalian cell and a suitable growth medium.
- the growth medium may in the form of a liquid; alternatively, it is in the form of solid agar.
- the growth medium is comprised of components well known to those skilled in the art. Realisation of said culturing can be accomplished by conventional techniques, including:
- a suitably shaped gelatine-based sponge positioned at the end of a stick is used to collect targets from a surface, and subsequently allowed to come into contact with a growth medium, such that micro-organisms or mammalian cells collected by the sponge are transferred to the growth medium.
- a liquid growth medium optionally agar-containing, into the gelatine sponge, thus providing conditions for in situ growth of the bound micro-organisms or mammalian cells in the gelatine-based sponge.
- the culturing of collected micro-organisms or mammalian cells may be preceded by a step in which bound cells have been unbound or by other means released into a medium.
- said medium is considered to be a first transfer medium.
- the medium can be any liquid suitable for the application, such as a neutral diluent, a dispersion agent, or a growth medium.
- Unbinding of bound micro-organisms or mammalian cells may be realized by any of the methods described herein, including enzymatic and/or chemical digestion of the gelatine-based sponge, and may include mechanical transfer into said first transfer medium.
- the thus unbound micro-organisms or mammalian cells are subsequently transferred to a second transfer medium, which is ideally comprised of a liquid or solid growth medium.
- the transfer to a second transfer medium may be partial, i.e. a sample from said first growth medium is transferred to said second transfer medium.
- the transfer is complete, i.e. the entire volume of the first transfer medium is transferred into the second tranfer medium. Culturing of micro-organisms or mammalian cells collected by the gelatine-based sponge of the invention may in particular be useful for further characterization or production of the collected micro-organisms or mammalian cells.
- the gelatine-based sponge may, for example, be used for qualitative determination of the microbiological and/or mammalian cell composition of a target population collected from a sample.
- the sample may, for example, be a surface in a food production line, such as meat or fish processing lines, or from other surfaces such as floors, walls, or equipment used in such processing lines.
- the sample may be a surface from equipment, specialized furniture or walls or floors from a health clinic or hospitals, such as surgical rooms.
- the sample may also be collected from an open wound, from the surface of an internal organ or it may be comprised of any mammalian tissue.
- the gelatine-based sponge may be adapted for collecting and culturing targets from any sample, from which it is useful to determine the microbiological and/or mammalian cell content.
- the collection medium is a solid surface from which targets may be collected.
- the medium is a liquid, from which targets may also be collected.
- the high water absorption capacity of the gelatine-based sponge is a useful characteristic, as it allows collection of large volumes of water.
- the liquid medium may be located on a surface, for example in cavities on the surface. The sponge therefore can be adapted to be useful for the collection of targets from a wide variety of sources, such as manufacturing devices in food manufacturing, processing plants for meat and/or fish products, medical devices, as well as the management and cleaning of wounds, such as surgical wounds.
- gelatine-based sponge may be adapted for use in collecting targets from other types of samples of liquid and/or gaseous nature.
- collection may be from a solid surface irrespective of the material from which the surface is comprised, such as natural or synthetic surfaces, of organic or inorganic material.
- targets may be collected from semi-solid surfaces, such as mammalian surfaces and mammalian tissue, including mammalian skin and the surface of mammalian organs.
- the following methods and examples illustrate how the gelatine-based sponge of the present invention may for specific uses be adapted for the collection and recovery of bacterial spores from a stainless steel surface.
- Recovery yields i.e. the overall yields for the transfer from the surface to the sponge and the subsequent transfer from the sponge to a medium, are very high which is an illustration of the usefulness of the gelatine-based sponge for the collection and transfer of targets from a sample, such as a stainless steel surface.
- the purpose of this method is to determine the reconfirmation rate of a gelatine-based sponge.
- the method comprises soaking the sponge, and subsequently squeezing it.
- the appearance of the native shape of the sponge is monitored as a function of time, and the time that lapses until the sponge has reached its native shape is termed the reconfirmation time.
- the method comprises the following steps:
- Example 3 Determination of water absorption of gelatine-based sponges Purpose: To determine the amount of water that a gelatine-based sponge can absorb. The sponge is expected to absorb several times its own weight of water on a weight to weight basis. Method: According to USP Method "Absorable Gelatine Sponge: Water absorption”. A total of 6 determinations on 6 different pieces of gelatine-based sponge are performed.
- the dimensions weight, height, length, width, centre hole and diameter of the gelatine sponge are measured on 6 samples; one series of measurements is performed for each of the 6 samples. The average of the 6 measurements is reported. The density is calculated.
- Apparatus A caliper, Mitutoyo 500-Series or similar.
- a ruler specifically made for the determination of length and width of absorbable gelatine sponge film.
- the weight of the sponge is measured. The average of 6 measurements performed on 6 samples is reported (in 0.001 g).
- the density of the absorbable gelatine sponge, anal is calculated in the following way:
- D diameter of the sponge
- d diameter of the pore in the sponge.
- Example 5 Sampling protocol from a stainless steel surface using wet sampling and dry sampling.
- the Count-Tact applicator standardizes surface testing, by applying a uniform pressure of 500 ⁇ 50 g for 10 + 1 seconds (draft European Standard: CEN/TC 243).
- the applicator is composed of two plastic elements:
- the base which holds the Count-Tact plate in position, consisting of a push-button device mounted on a calibrated spring;
- the method involves the following steps: 1. Slide the Count-Tact plate into position (lid facing outwards) under the two transparent clips fixed on the bottom of the base.
- This protocol describes the validation of a method that is used for the microbiological sampling from polished stainless steel, which has been cleaned with isopropanol 70%.
- the validation protocol is carried out in order to define the accuracy and precision of the method, and the recovery yield of micro-organisms from the type of material used in this test, using the described method of sampling.
- This current test does apply whenever microbiological sampling from polished stainless steel cleaned with isopropanol is carried out in accordance with the current described sampling procedures.
- Bacillus spores are used as markers of microbiological activity on the stainless steel. Because the spores are incubated at 55°C, it is considered unlikely that any microbiological contamination will influence the results during the validation test. Thus, selectivity is not relevant for this test.
- Test is carried out in six replicates, using three concentration levels (5, 25 and 50 spores), and 2 wipings of each surface material, pooled for analysis.
- Class A Spore supsensions containing 5 spores/313 ⁇ L is used as positive control.
- Class B Spore supsensions containing 25 spores/63 ⁇ L is used as positive control.
- Three spore suspensions a) containing 5 spores, b) containing 25 spores and c) containing 50 spores will be used for the linearity study.
- Negative controls are also added to the stainless steel sheets. Positive control samples are not added to stainless steel sheets, but are added directly to the Count-Tact application plates.
- All samples are incubated at 55C ⁇ 2C for at least 1 day to a maximum of 7 days.
- Recovery/Precision and Accuracy is investigated using stainless steel and performed in accordance with the methods outlined above. This test will be used for the calculation of the microbiological recovery from the test samples. Batches of reagents and equipment will not be altered since the change in these parameters is estimated to have little or no influence on the final test results.
- Each stainless steel sheet is swabbed quadruplicate or sampled using the Count-Tact applicator
- the samples are incubated at 55 ⁇ 2C for at least 1 day to a maximum of 7 days and counted.
- the tests will be carried out in accordance with the method described above.
- Procedure Prepare six identical samples using the spore suspensions a), b) and c) defined above. The samples will be used to establish recovery efficiencies for these levels of spores and used for the subsequent linear regression.
- Evaluation - recovery will be calculated for each level of spores and regression will be made from 5 to 50 spores. - calculate the regression parameters of the standard curves and report slope, intercept and correlation coefficient of each curve.
- Example 8 Validation of sampling from polished stainless steel.
- the validation study is carried out in order to define the accuracy, precision and linearity of methods used for microbiological sampling from surfaces and to estimate the recovery efficienty of micro-organisms from the type of material used in the test, using the described methods of sampling.
- the sampling was performed from polished stainless steel cleaned with 70% isopropanol.
- the rationale for sampling is that this is a common material used for equiment production.
- the method tested were sampling by swab technique and sampling by count-tact technique.
- the sampling was carried out on surfaces with an applied number of bacterial spores equal to the USP, NF guideline of class 10,000 production equipment and the EU-GMP guideline for microbiological purity of class 10,000 production equipment.
- the number of spores applied was calculated to be 5, 25 or 50.
- the actual amound of spores applied was used for calculating recoveries.
- One analyst only carried out sampling from surfaces with 50 spores applied by the sole purpose of investigating linearity
- Linearity was calculated by regression between applied spore concentrations of 5, 25 and 50 spores by one analyst.
- the defined level of acceptance was a R 2 >0,9400.
- the calculated R 2 was 0,9990 when using the swab technique and 0,9989 when using the count-tact technique.
- the number of spores applied was calculated to be 5, 25 or 50.
- the actual amound of spores applied was used for calculating recoveries.
- the level of recovery of microorganisms from surfaces is critical when complying with USP/NF guidelines and EU-GMP guidelines.
- the bacterial recovery using both the swab technique and the count-tact technique as described in the protocol was better than anticipated when recovering microorganisms from the samples with a known microbiological contamination rqual to the USP/NF guideline and the EU-GMP guideline.
- the average (for all analysts) lowest recovery was 80% for the swab technique and 45% for the count-tact technique. For the chosen sampling method used on stainless steel this recovery should be used to estimate the actual amount of microorganism on the surface.
- %RSD relative standard deviation
- the average %RSD calculated for the lowest recoveries given above was 64% for the swab technique and 54% for the count-tact method. To correct for the large variations on the analysis the %RSD should be taken into account when estimating the actual number of microorganisms on a surface.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200380108960XA CN1739017B (en) | 2002-12-11 | 2003-12-11 | Gelatine-based materials as swabs |
AU2003302906A AU2003302906B2 (en) | 2002-12-11 | 2003-12-11 | Gelatine-based materials as swabs |
JP2004557825A JP2006509502A (en) | 2002-12-11 | 2003-12-11 | Gelatin-based material as a swab |
MXPA05006193A MXPA05006193A (en) | 2002-12-11 | 2003-12-11 | Gelatine-based materials as swabs. |
CA002509914A CA2509914A1 (en) | 2002-12-11 | 2003-12-11 | Gelatine-based materials as swabs |
BR0317237-6A BR0317237A (en) | 2002-12-11 | 2003-12-11 | Sampling or collecting device, kit, uses of a device and a kit, and methods for decreasing the amount of a marker in a sample area, for qualitatively or quantitatively sampling an area for the content of a marker and for grow microorganisms or mammalian cells collected |
EP03812570A EP1573295A2 (en) | 2002-12-11 | 2003-12-11 | Gelatine-based materials as swabs |
US10/538,918 US7955288B2 (en) | 2002-12-11 | 2003-12-11 | Gelatine-based materials as swabs |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43223202P | 2002-12-11 | 2002-12-11 | |
US60/432,232 | 2002-12-11 | ||
DKPA200201896 | 2002-12-11 | ||
DKPA200201896 | 2002-12-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004053051A2 true WO2004053051A2 (en) | 2004-06-24 |
WO2004053051A3 WO2004053051A3 (en) | 2005-03-10 |
Family
ID=36081240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2003/000855 WO2004053051A2 (en) | 2002-12-11 | 2003-12-11 | Gelatine-based materials as swabs |
Country Status (10)
Country | Link |
---|---|
US (1) | US7955288B2 (en) |
EP (1) | EP1573295A2 (en) |
JP (1) | JP2006509502A (en) |
CN (1) | CN1739017B (en) |
AU (1) | AU2003302906B2 (en) |
BR (1) | BR0317237A (en) |
CA (1) | CA2509914A1 (en) |
MX (1) | MXPA05006193A (en) |
PL (1) | PL377477A1 (en) |
WO (1) | WO2004053051A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004081514A2 (en) * | 2003-03-12 | 2004-09-23 | Charite - Universitätsmedizin Berlin | Device and method for in vivo cell transfer |
WO2008080932A1 (en) * | 2006-12-29 | 2008-07-10 | Preanalytix Gmbh | Device for collecting and triggered release of a biological sample |
WO2009113944A1 (en) * | 2008-03-12 | 2009-09-17 | Hector Roldan | Sampling kit |
FR2949477A1 (en) * | 2009-09-03 | 2011-03-04 | Millipore Corp | METHOD AND DEVICE FOR SAMPLING SURFACE ANALYSIS |
US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
US8628953B2 (en) | 2007-11-29 | 2014-01-14 | Hitachi Plant Technologies, Ltd. | Capturing carrier, capturing device, analysis system using the same, and method for capturing and testing microorganisms |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US9999703B2 (en) | 2012-06-12 | 2018-06-19 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040121379A1 (en) * | 2002-10-11 | 2004-06-24 | Ohan Mark Peter | Methods and devices for acquisition of genetic material |
ITMI20030643A1 (en) * | 2003-04-01 | 2004-10-02 | Copan Innovation Ltd | BUFFER FOR THE COLLECTION OF BIOLOGICAL SAMPLES |
AU2005262070B2 (en) * | 2004-07-09 | 2011-01-27 | Ferrosan Medical Devices A/S | Haemostatic composition comprising hyaluronic acid |
DK2148743T3 (en) * | 2007-05-17 | 2018-06-06 | Advance Dx Inc | Liquid separator collection card |
WO2009020782A2 (en) * | 2007-08-06 | 2009-02-12 | Oft Labs Llc | Oral fluid assays for the detection of heavy metal exposure |
DE102007044648B4 (en) * | 2007-09-18 | 2020-11-26 | Carl Freudenberg Kg | Bioresorbable gelatin non-woven fabric |
RU2545810C2 (en) | 2008-02-29 | 2015-04-10 | Ферросан Медикал Дивайсиз А/С | Device for fastening haemostasis and/or wound healing |
JP5453529B2 (en) | 2010-04-21 | 2014-03-26 | ピュリタン・メディカル・プロダクツ・カンパニー・エルエルシー | Harvesting devices and materials |
IT1401447B1 (en) * | 2010-06-09 | 2013-07-26 | Copan Italia Spa | METHOD FOR THE QUANTITATIVE TRANSFER OF ANALYTES |
IT1403618B1 (en) | 2011-01-05 | 2013-10-31 | Copan Italia Spa | PROCEDURE FOR REALIZING A DEVICE FOR THE COLLECTION AND TRANSFER OF SAMPLES FOR MOLECULAR BIOLOGY |
ITMI20121603A1 (en) | 2012-09-25 | 2014-03-26 | Copan Italia Spa | DEVICE AND METHOD FOR THE COLLECTION AND TRANSFER OF SAMPLES OF BIOLOGICAL MATERIAL |
US10088397B2 (en) | 2013-06-19 | 2018-10-02 | Advance Dx, Inc. | Fluid separator collection card assembly |
US10946376B2 (en) * | 2013-07-05 | 2021-03-16 | Thinxxs Microtechnology Ag | Carrier element for introducing a dry substance into a flow cell |
CN105255718A (en) * | 2015-10-16 | 2016-01-20 | 广东海大集团股份有限公司 | Testing cotton swab as well as preparation method and testing method thereof |
US10532128B2 (en) * | 2015-11-18 | 2020-01-14 | Viera Bioscience, Inc. | Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction |
US10610862B2 (en) | 2016-04-04 | 2020-04-07 | Advance Dx, Inc. | Multiple path sample collection card |
WO2019060276A1 (en) | 2017-09-21 | 2019-03-28 | Becton, Dickinson And Company | Augmented reality devices for hazardous contaminant testing |
CA3075771A1 (en) | 2017-09-21 | 2019-03-28 | Becton, Dickinson And Company | Reactive demarcation template for hazardous contaminant testing |
CN117405433A (en) | 2017-09-21 | 2024-01-16 | 贝克顿·迪金森公司 | Dangerous pollutant collecting kit and rapid test |
JP7344198B2 (en) | 2017-09-21 | 2023-09-13 | ベクトン・ディキンソン・アンド・カンパニー | Boundary template for testing hazardous contaminants |
WO2019060265A1 (en) | 2017-09-21 | 2019-03-28 | Becton, Dickinson And Company | Sampling systems and techniques to collect hazardous contaminants with high pickup and shedding efficiencies |
WO2019060270A1 (en) | 2017-09-21 | 2019-03-28 | Becton, Dickinson And Company | High dynamic range assays in hazardous contaminant testing |
US11585733B2 (en) | 2017-09-21 | 2023-02-21 | Becton, Dickinson And Company | Hazardous contaminant collection kit and rapid testing |
CN108414295B (en) * | 2018-03-07 | 2021-06-29 | 广东诺瓦安评检测有限公司 | Sampling device and sampling method for industrial enzyme mixed dust in air of workplace |
WO2020159790A1 (en) | 2019-01-28 | 2020-08-06 | Becton, Dickinson And Company | Hazardous contaminant collection device with integrated swab and test device |
EP4352501A1 (en) * | 2021-06-07 | 2024-04-17 | Regents of the University of Minnesota | Methods and materials for detecting prion diseases |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2465357A (en) * | 1944-08-14 | 1949-03-29 | Upjohn Co | Therapeutic sponge and method of making |
GB697603A (en) * | 1948-10-06 | 1953-09-23 | Sydney Arthur Gladstone | Improvements in or relating to method of and devices for obtaining tissue from a tumour carried by a patient |
US3224434A (en) * | 1962-11-06 | 1965-12-21 | Waldemar Medical Res Foundatio | Cell collector |
US3815580A (en) * | 1972-08-31 | 1974-06-11 | C Oster | Apparatus for and method of collecting and preserving cytologic samples |
US4098728A (en) * | 1976-01-02 | 1978-07-04 | Solomon Rosenblatt | Medical surgical sponge and method of making same |
US4492305A (en) * | 1983-07-08 | 1985-01-08 | Marion Laboratories, Inc. | Package for collecting cultures |
EP0156649A2 (en) * | 1984-03-29 | 1985-10-02 | Minnesota Mining And Manufacturing Company | Sorbent sheet material |
US4997753A (en) * | 1985-04-04 | 1991-03-05 | Verax Corporation | Weighted collagen microsponge for immobilizing bioactive material |
US5462860A (en) * | 1994-06-06 | 1995-10-31 | Minnesota Mining And Manufacturing Company | Conditioned culture medium for rapid growth and detection of microbes |
EP0702081A2 (en) * | 1994-09-19 | 1996-03-20 | Gunze Limited | Matrix for tissue culture, method for culturing tissue, method for fixing cultured tissue and artificial skin fixed |
WO1998043092A1 (en) * | 1997-03-24 | 1998-10-01 | Baystate Medical Center | Method for determining the presence of mutated brca protein |
WO1999012032A1 (en) * | 1997-09-04 | 1999-03-11 | Pharmacia & Upjohn Company | A method for the evaluation of antiviral drugs |
US5939259A (en) * | 1997-04-09 | 1999-08-17 | Schleicher & Schuell, Inc. | Methods and devices for collecting and storing clinical samples for genetic analysis |
US6045570A (en) * | 1997-02-11 | 2000-04-04 | Biointerventional Corporation | Biological sealant mixture and system for use in percutaneous occlusion of puncture sites and tracts in the human body and method |
WO2001034206A2 (en) * | 1999-11-09 | 2001-05-17 | Cmic Co., Ltd. | Nucleic acid-containing complex |
US6261596B1 (en) * | 1993-04-02 | 2001-07-17 | Anticancer, Inc. | Method to provide for production of hair coloring pigments in hair follicles |
US20010041913A1 (en) * | 1998-05-01 | 2001-11-15 | Cragg Andrew H. | Device and method for facilitating hemostasis of a biopsy tract |
US20020010482A1 (en) * | 1997-10-03 | 2002-01-24 | Watt Paul W. | Biopolymer sponge tubes, surgical staplers and methods of use thereof |
Family Cites Families (173)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2465860A (en) * | 1945-10-13 | 1949-03-29 | Standard Manifold Company Inc | Carbon holder |
GB648619A (en) | 1947-03-19 | 1951-01-10 | Ferrosan As | Process of producing sponges of gelatine and the like proteins |
CH264752A (en) * | 1947-06-03 | 1949-10-31 | Hoffmann La Roche | Process for the manufacture of carriers for pharmaceuticals. |
US3869539A (en) * | 1966-12-01 | 1975-03-04 | Ferrosan As | Preparations containing fat-soluble vitamins in dry, particulate, free-flowing form dispersible in cold water and method of producing such preparations |
CA930128A (en) * | 1969-10-21 | 1973-07-17 | Torr David | Fiber products containing water-absorbent material |
US3678933A (en) * | 1970-07-17 | 1972-07-25 | Moore Perk Corp | Surgical sponge or bandage |
FR2167197B1 (en) | 1972-01-10 | 1974-06-21 | Pont Brule Sa | IMPROVED COMPOSITIONS CONTAINING GELATIN |
US4280954A (en) * | 1975-07-15 | 1981-07-28 | Massachusetts Institute Of Technology | Crosslinked collagen-mucopolysaccharide composite materials |
GB1584080A (en) | 1977-12-05 | 1981-02-04 | Ethicon Inc | Absorbable hemostatic composition |
US4265233A (en) * | 1978-04-12 | 1981-05-05 | Unitika Ltd. | Material for wound healing |
DE2943520C2 (en) * | 1979-10-27 | 1982-05-19 | Fa. Carl Freudenberg, 6940 Weinheim | Process for the production of collagen sponge for medical or cosmetic purposes |
US4460642A (en) * | 1981-06-26 | 1984-07-17 | Minnesota Mining And Manufacturing Company | Water-swellable composite sheet of microfibers of PTFE and hydrophilic absorptive particles |
DE3146841A1 (en) | 1981-11-26 | 1983-06-01 | Beiersdorf Ag, 2000 Hamburg | Wound-treatment compositions |
JPS5928472A (en) | 1982-08-09 | 1984-02-15 | Koken:Kk | Substrate for cell culture, cultivation and separation of cell using it |
US4515637A (en) * | 1983-11-16 | 1985-05-07 | Seton Company | Collagen-thrombin compositions |
US4522302A (en) * | 1984-03-05 | 1985-06-11 | Sterling Drug Inc. | Pre-sterilized medical procedure kit packages |
US4717667A (en) * | 1984-07-11 | 1988-01-05 | Fmc Corporation | Colony replicating device |
JPS6144825A (en) * | 1984-08-09 | 1986-03-04 | Unitika Ltd | Hemostatic agent |
JPS61122222A (en) * | 1984-11-19 | 1986-06-10 | Koken:Kk | Hemostatic agent composed of collagen or gelatin and protamine |
JPS61209590A (en) * | 1985-03-13 | 1986-09-17 | Asama Kasei Kk | Novel immobilized cell and method for fermentative production utilizing same |
US4863856A (en) | 1985-04-04 | 1989-09-05 | Verax Corporation | Weighted collagen microsponge for immobilizing bioactive materials |
US4861714A (en) | 1985-04-04 | 1989-08-29 | Verax Corporation | Weighted collagen microsponge for immobilizing bioactive material |
AT382783B (en) * | 1985-06-20 | 1987-04-10 | Immuno Ag | DEVICE FOR APPLICATING A TISSUE ADHESIVE |
US5112750A (en) * | 1985-06-25 | 1992-05-12 | Asama Chemical Co., Ltd. | Immobilized cells and culture method utilizing the same |
US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
US4696812A (en) | 1985-10-28 | 1987-09-29 | Warner-Lambert Company | Thrombin preparations |
US5180583A (en) * | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
US20020192271A1 (en) | 1985-11-26 | 2002-12-19 | Hedner Ulla Karin Elisabeth | Method for causing local hemostasis and hemostatic composition for local hemostasis |
US5690954A (en) | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
JPS6485653A (en) | 1987-09-28 | 1989-03-30 | Terumo Corp | Drug receiving container |
IT1219587B (en) | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES |
US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
EP0365705A1 (en) | 1988-10-26 | 1990-05-02 | Zentralna Problemna Laboratoria Po Kryobiologia I Lyophilisazia | Biopreparation for the treatment of wounds |
US4891359A (en) * | 1988-12-08 | 1990-01-02 | Johnson & Johnson Patient Care, Inc. | Hemostatic collagen paste composition |
US5356883A (en) | 1989-08-01 | 1994-10-18 | Research Foundation Of State University Of N.Y. | Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use |
JPH03217051A (en) * | 1990-01-23 | 1991-09-24 | Oki Electric Ind Co Ltd | Semiconductor memory |
US4982769A (en) * | 1990-02-21 | 1991-01-08 | Survival Technology, Inc. | Package |
JPH0813750B2 (en) | 1990-03-01 | 1996-02-14 | 持田製薬株式会社 | Oral thrombin formulation |
US5595735A (en) * | 1990-05-23 | 1997-01-21 | Johnson & Johnson Medical, Inc. | Hemostatic thrombin paste composition |
DE59005286D1 (en) | 1990-10-04 | 1994-05-11 | Kallies Import Export Vertrieb | Stabilized thrombin, its preparation and its use as a thrombin time reagent. |
JP2990789B2 (en) * | 1990-11-14 | 1999-12-13 | 東レ株式会社 | Culture method of vascular endothelial cells |
US5690675A (en) | 1991-02-13 | 1997-11-25 | Fusion Medical Technologies, Inc. | Methods for sealing of staples and other fasteners in tissue |
EP0572526A4 (en) | 1991-02-13 | 1995-12-06 | Interface Biomedical Lab Corp | Filler material for use in tissue welding |
US5749895A (en) * | 1991-02-13 | 1998-05-12 | Fusion Medical Technologies, Inc. | Method for bonding or fusion of biological tissue and material |
US5669934A (en) | 1991-02-13 | 1997-09-23 | Fusion Medical Technologies, Inc. | Methods for joining tissue by applying radiofrequency energy to performed collagen films and sheets |
EP0525132B1 (en) | 1991-02-14 | 1996-01-03 | Baxter International Inc. | Binding of recognizing substances to liposomes |
DE4119140C2 (en) | 1991-06-11 | 1994-05-11 | Merz & Co Gmbh & Co | Porous spongeoid moldings soluble in body fluids and secretions, their preparation and use |
FR2679772B1 (en) | 1991-08-02 | 1995-05-19 | Peters Sa | EMBOLS IN NON-RESORBABLE PARTICLES COATED WITH HEMOSTATIC MATERIAL. |
IT1251151B (en) * | 1991-08-05 | 1995-05-04 | Fidia Spa | SPONGY MATERIAL ESSENTIALLY CONSTITUTED BY HYALURONIC ACID, OR ITS DERIVATIVES |
US6620436B1 (en) | 1991-10-09 | 2003-09-16 | Lectec Corporation | Mixing and dispensing package for a wound dressing |
GB2266239B (en) | 1992-03-25 | 1996-03-06 | Jevco Ltd | Wound healing compositions containing chondroitin sulphate oligosaccharides |
GB9206509D0 (en) * | 1992-03-25 | 1992-05-06 | Jevco Ltd | Heteromorphic sponges containing active agents |
IL105529A0 (en) * | 1992-05-01 | 1993-08-18 | Amgen Inc | Collagen-containing sponges as drug delivery for proteins |
US5443481A (en) * | 1992-07-27 | 1995-08-22 | Lee; Benjamin I. | Methods and device for percutaneous sealing of arterial puncture sites |
WO1994006460A1 (en) | 1992-09-21 | 1994-03-31 | Vitaphore Corporation | Embolization plugs for blood vessels |
US5334216A (en) | 1992-12-10 | 1994-08-02 | Howmedica Inc. | Hemostatic plug |
JP3237799B2 (en) * | 1993-04-06 | 2001-12-10 | オリンパス光学工業株式会社 | Automatic cleaning equipment for continuous processing tools for various liquids |
AU6705894A (en) | 1993-04-20 | 1994-11-08 | Medchem Products, Inc. | Apparatus and method for applying a particulate hemostatic agent to living tissue |
US5723308A (en) * | 1993-05-14 | 1998-03-03 | Minnesota Mining And Manufacturing Company | Culture medium for rapid count of coliform bacteria |
US5951583A (en) | 1993-05-25 | 1999-09-14 | Vascular Solutions, Inc. | Thrombin and collagen procoagulant and process for making the same |
US5387208A (en) * | 1993-07-26 | 1995-02-07 | The Procter & Gamble Co. | Absorbent core having improved dry/wet integrity |
US5798091A (en) * | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
US5394886A (en) * | 1993-09-20 | 1995-03-07 | Nabai; Hossein | Skin biopsy plug and method |
EP0726749B1 (en) * | 1993-11-03 | 2004-08-11 | Clarion Pharmaceuticals, Inc. | Hemostatic patch |
WO1995018216A1 (en) * | 1993-12-30 | 1995-07-06 | Nitta Gelatin Inc. | Process for embedding culture of animal cells |
DE4407875C2 (en) | 1994-03-04 | 1996-04-04 | Ankerpharm Gmbh Ankerwerk Rudo | Medical sponge made from bioabsorbable materials, process and device for its production |
ITPD940054A1 (en) * | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | SULPHATED POLYSACCHARIDES |
CA2146090C (en) | 1994-05-10 | 1998-11-24 | Mark E. Mitchell | Apparatus and method of mixing materials in a sterile environment |
US5931165A (en) | 1994-09-06 | 1999-08-03 | Fusion Medical Technologies, Inc. | Films having improved characteristics and methods for their preparation and use |
FR2726571B1 (en) | 1994-11-03 | 1997-08-08 | Izoret Georges | BIOLOGICAL GLUE, PREPARATION METHOD AND APPLICATION DEVICE FOR BIOLOGICAL GLUE, AND HARDENERS FOR BIOLOGICAL GLUE |
JPH08140692A (en) * | 1994-11-25 | 1996-06-04 | Toray Ind Inc | Production of von wilebrand factor |
US5660854A (en) * | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US5804203A (en) * | 1994-12-21 | 1998-09-08 | Cosmederm Technologies | Topical product formulations containing strontium for reducing skin irritation |
JPH11502431A (en) * | 1995-01-16 | 1999-03-02 | バクスター インターナショナル インコーポレイテッド | Self-supporting sheet-like material of cross-linked fibrin to prevent post-operative adhesions |
DE19513666C1 (en) * | 1995-04-11 | 1996-11-28 | Behringwerke Ag | Device for bringing together a first liquid and a second solid or liquid component by means of negative pressure under sterile conditions |
JP3799626B2 (en) | 1995-04-25 | 2006-07-19 | 有限会社ナイセム | Cardiovascular repair material and method for producing the same |
DE19521324C1 (en) * | 1995-06-12 | 1996-10-31 | Immuno Ag | Tissue adhesive and use thereof as a hemostatic |
AU7398196A (en) * | 1995-10-11 | 1997-04-30 | Fusion Medical Technologies, Inc. | Device and method for sealing tissue |
HUP9903586A3 (en) | 1996-04-04 | 2003-02-28 | Baxter Ag | Hemostatic sponge based on collagen |
US5948427A (en) * | 1996-04-25 | 1999-09-07 | Point Medical Corporation | Microparticulate surgical adhesive |
US5791352A (en) * | 1996-06-19 | 1998-08-11 | Fusion Medical Technologies, Inc. | Methods and compositions for inhibiting tissue adhesion |
AU3720097A (en) | 1996-07-12 | 1998-02-09 | Baxter International Inc. | A fibrin delivery device and method for forming fibrin on a surface |
US6066325A (en) | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6063061A (en) * | 1996-08-27 | 2000-05-16 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US7320962B2 (en) | 1996-08-27 | 2008-01-22 | Baxter International Inc. | Hemoactive compositions and methods for their manufacture and use |
US7435425B2 (en) * | 2001-07-17 | 2008-10-14 | Baxter International, Inc. | Dry hemostatic compositions and methods for their preparation |
US6706690B2 (en) * | 1999-06-10 | 2004-03-16 | Baxter Healthcare Corporation | Hemoactive compositions and methods for their manufacture and use |
CA2211629A1 (en) * | 1996-09-17 | 1998-03-17 | Bernard Sams | Vial connector assembly for a medicament container |
US5795330A (en) * | 1996-10-10 | 1998-08-18 | Etex Corporation | Mixing device |
US5743412A (en) * | 1996-11-13 | 1998-04-28 | Chrysler Corporation | Modular parts supply rack |
US5782860A (en) | 1997-02-11 | 1998-07-21 | Biointerventional Corporation | Closure device for percutaneous occlusion of puncture sites and tracts in the human body and method |
US5905029A (en) * | 1997-02-19 | 1999-05-18 | Fritz Berthold | Method for rapid hygiene testing |
FR2759980A1 (en) | 1997-02-25 | 1998-08-28 | Bras Michel | Container for mixable food ingredients |
US6716435B1 (en) * | 1997-04-18 | 2004-04-06 | Ganeden Biotech, Inc. | Absorbent product containing absorbent structure and Bacillus coagulans |
US20020039594A1 (en) * | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
US5957166A (en) | 1997-06-16 | 1999-09-28 | Fusion Medical Technologies, Inc. | Method and apparatus for dispersing fluid into a material |
US5908054A (en) * | 1997-06-16 | 1999-06-01 | Fusion Medical Technologies, Inc. | Fluid dispersion and delivery assembly and method |
JP2002514960A (en) | 1997-06-18 | 2002-05-21 | コヘージョン テクノロジーズ,インコーポレイテッド | Compositions comprising thrombin and microfibril collagen and methods for their preparation and use |
US6042262A (en) * | 1997-07-29 | 2000-03-28 | Stryker Technologies Corportion | Apparatus for storing, mixing, and dispensing two-component bone cement |
ZA987019B (en) | 1997-08-06 | 1999-06-04 | Focal Inc | Hemostatic tissue sealants |
JPH1156343A (en) * | 1997-08-21 | 1999-03-02 | Able Kk | Fixed bed reactor for culturing animal cell and sowing of cell |
WO1999010385A1 (en) * | 1997-08-22 | 1999-03-04 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid gel, process for producing the same and medical material containing the same |
US6168788B1 (en) * | 1997-09-26 | 2001-01-02 | Leon Wortham | Fibrin glue without fibrinogen and biosealant compositions and methods |
US6303323B1 (en) * | 1997-10-21 | 2001-10-16 | Cancer Research Campaign Technology Limited | Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies |
JP3483753B2 (en) | 1997-12-29 | 2004-01-06 | タキロン株式会社 | Biodegradable absorbent plastic adhesive |
US7722671B1 (en) * | 1998-01-27 | 2010-05-25 | St. Jude Medical, Inc. | Medical devices with associated growth factors |
US6099952A (en) | 1998-02-18 | 2000-08-08 | Xomed Surgical Products, Inc. | Medical sponge having mucopolysaccharide coating |
ATE371472T1 (en) | 1998-03-06 | 2007-09-15 | Baxter Int | TURBULENCY MIXING HEAD FOR TISSUE ADHESIVE APPLICATOR AND SPRAY HEAD FOR THE SAME |
US20020025921A1 (en) * | 1999-07-26 | 2002-02-28 | Petito George D. | Composition and method for growing, protecting, and healing tissues and cells |
US20020061842A1 (en) * | 1998-04-10 | 2002-05-23 | Octapharma Ag | Method for sterilizing a native collagen in liquid medium, sterile native collagen obtained, compositions containing it and uses |
ITPD980169A1 (en) | 1998-07-06 | 2000-01-06 | Fidia Advanced Biopolymers Srl | AMIDES OF HYALURONIC ACID AND ITS DERIVATIVES AND PROCESS FOR THEIR PREPARATION. |
US6334865B1 (en) * | 1998-08-04 | 2002-01-01 | Fusion Medical Technologies, Inc. | Percutaneous tissue track closure assembly and method |
JP2003521270A (en) * | 1998-08-04 | 2003-07-15 | フュージョン メディカル テクノロジーズ, インコーポレイテッド | Percutaneous tissue tract occlusion assemblies and methods |
US6613070B2 (en) * | 1998-08-04 | 2003-09-02 | Baxter International Inc. | System and method for sealing vascular penetrations with hemostatic gels |
US20020015724A1 (en) * | 1998-08-10 | 2002-02-07 | Chunlin Yang | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing |
US6454787B1 (en) | 1998-12-11 | 2002-09-24 | C. R. Bard, Inc. | Collagen hemostatic foam |
KR100804434B1 (en) | 1998-12-23 | 2008-02-20 | 체에스엘 베링 게엠베하 | Fibrin-based glue granulate and corresponding production method |
US6283933B1 (en) * | 1998-12-23 | 2001-09-04 | Closure Medical Corporation | Applicator for dispensable liquids |
US6977231B1 (en) | 1999-01-21 | 2005-12-20 | Nipro Corporation | Suturable adhesion-preventing membrane |
US6862470B2 (en) | 1999-02-02 | 2005-03-01 | Senorx, Inc. | Cavity-filling biopsy site markers |
WO2000049084A1 (en) | 1999-02-19 | 2000-08-24 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid gel composition, process for producing the same, and medical material containing the same |
US6312725B1 (en) | 1999-04-16 | 2001-11-06 | Cohesion Technologies, Inc. | Rapid gelling biocompatible polymer composition |
EP1053758A1 (en) | 1999-05-19 | 2000-11-22 | Resorba Chirurgisches Nahtmaterial Franz Hiltner GmbH & Co. | Bioabsorbable implant |
US20020019062A1 (en) * | 1999-06-18 | 2002-02-14 | Peter Lea | Assay devices |
DK1218437T3 (en) | 1999-08-27 | 2009-10-19 | Angiodevice Internat Gmbh | Preparations forming interpenetrating polymer networks for use as high-strength medical sealants |
US20030095993A1 (en) * | 2000-01-28 | 2003-05-22 | Hanne Bentz | Gel-infused sponges for tissue repair and augmentation |
IT1317832B1 (en) * | 2000-02-15 | 2003-07-15 | Eurores S R L | PROCEDURE FOR THE PREPARATION OF MICRONIZED COLLAGEN AND THERAPEUTIC APPLICATIONS. |
US20010038848A1 (en) | 2000-02-18 | 2001-11-08 | Donda Russell S. | Implantable tissues infused with growth factors and other additives |
EP1149906A1 (en) | 2000-04-25 | 2001-10-31 | Pliva, Farmaceutska, Industrija, Dionicko Drustvo | Thrombopoietin receptor modulating peptide |
JP2003531682A (en) * | 2000-04-28 | 2003-10-28 | フジオメッド インコーポレイテッド | Hemostatic compositions of polyacids and polyalkylene oxides and methods of using the same |
AT412445B (en) * | 2000-06-20 | 2005-03-25 | Biering Wolfgang | LIQUID COLLAGE HEMOSTATIC |
NZ523831A (en) * | 2000-07-13 | 2005-10-28 | Invitrogen Corp | Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix |
US20030032143A1 (en) * | 2000-07-24 | 2003-02-13 | Neff Thomas B. | Collagen type I and type III compositions for use as an adhesive and sealant |
DE60133744T2 (en) * | 2000-07-28 | 2009-05-14 | Anika Therapeutics, Inc., Woburn | BIOABSORBABLE COMPOSITE MATERIALS FROM DERIVATED HYALURONIC ACID |
US6890342B2 (en) * | 2000-08-02 | 2005-05-10 | Loma Linda University | Method and apparatus for closing vascular puncture using hemostatic material |
IT1317358B1 (en) | 2000-08-31 | 2003-06-16 | Fidia Advanced Biopolymers Srl | CROSS-LINKATED DERIVATIVES OF HYALURONIC ACID. |
US6364519B1 (en) * | 2000-09-26 | 2002-04-02 | Smith & Nephew, Inc. | Bone cement system |
US6635272B2 (en) | 2000-11-09 | 2003-10-21 | Richard N. Leaderman | Wound dressing and drug delivery system |
US6458380B1 (en) | 2000-11-09 | 2002-10-01 | Richard Leaderman | Dressing and preparation delivery system |
US20030009194A1 (en) * | 2000-12-07 | 2003-01-09 | Saker Mark B. | Tissue tract sealing device |
US7041868B2 (en) | 2000-12-29 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | Bioabsorbable wound dressing |
US6733774B2 (en) * | 2001-01-25 | 2004-05-11 | Nycomed Pharma As | Carrier with solid fibrinogen and solid thrombin |
US20020164322A1 (en) | 2001-01-25 | 2002-11-07 | Alfred Schaufler | Suspension comprising fibrinogen, thrombin and alcohol, a method for preparing such a suspension, a method for coating a carrier with such a suspension, a method of drying a coating of a carrier, and a coated collagen sponge |
US7052713B2 (en) * | 2001-02-13 | 2006-05-30 | Nycomed Pharma As | Carrier with solid fibrinogen and solid thrombin |
US8187625B2 (en) * | 2001-03-12 | 2012-05-29 | Boston Scientific Scimed, Inc. | Cross-linked gelatin composition comprising a wetting agent |
US6685745B2 (en) | 2001-05-15 | 2004-02-03 | Scimed Life Systems, Inc. | Delivering an agent to a patient's body |
BR0102637A (en) | 2001-05-17 | 2003-02-25 | Johnson & Johnson Ind Com | Adhesive bandage |
US7371403B2 (en) | 2002-06-14 | 2008-05-13 | Providence Health System-Oregon | Wound dressing and method for controlling severe, life-threatening bleeding |
JP4668510B2 (en) | 2001-09-29 | 2011-04-13 | 持田製薬株式会社 | Pharmaceutical composition for local hemostasis in a flexible container |
US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
US20060189516A1 (en) | 2002-02-19 | 2006-08-24 | Industrial Technology Research Institute | Method for producing cross-linked hyaluronic acid-protein bio-composites |
CN101898004A (en) | 2002-02-20 | 2010-12-01 | 21世纪国际新技术株式会社 | The device of drug administration |
NZ535136A (en) | 2002-02-21 | 2006-03-31 | Encelle Inc | Immobilized bioactive hydrogel matrices as surface coatings |
US20050137512A1 (en) * | 2003-12-23 | 2005-06-23 | Campbell Todd D. | Wound dressing and method for controlling severe, life-threatening bleeding |
US20040101546A1 (en) * | 2002-11-26 | 2004-05-27 | Gorman Anne Jessica | Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents |
US20040120993A1 (en) * | 2002-12-20 | 2004-06-24 | Guanghui Zhang | Hemostatic wound dressing and fabric and methods of making and using same |
ES2355723T3 (en) * | 2002-09-11 | 2011-03-30 | Elan Pharma International Limited | COMPOSITIONS OF ACTIVE AGENT IN GAN STABILIZED NANOPARTICLES. |
GB2393120A (en) | 2002-09-18 | 2004-03-24 | Johnson & Johnson Medical Ltd | Compositions for wound treatment |
US20040079763A1 (en) * | 2002-10-29 | 2004-04-29 | Powell Cindy Hagood | Duplex storage pouch |
US7112713B2 (en) | 2003-03-12 | 2006-09-26 | Gelsus Research And Consulting, Inc. | Dressing based on the Teorell-Meyer gradient |
US7129210B2 (en) * | 2003-07-23 | 2006-10-31 | Covalent Medical, Inc. | Tissue adhesive sealant |
US7109163B2 (en) | 2004-01-30 | 2006-09-19 | Ethicon, Inc. | Hemostatic compositions and devices |
US20050218541A1 (en) | 2004-04-02 | 2005-10-06 | Peng Henry T | Method of producing interpenetrating polymer network |
US20050245905A1 (en) | 2004-04-30 | 2005-11-03 | Schmidt Steven P | Local drug-delivery system |
GB2414021A (en) | 2004-05-10 | 2005-11-16 | Johnson & Johnson Medical Ltd | Absorbable haemostatic materials |
US7968085B2 (en) * | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
AU2005262070B2 (en) * | 2004-07-09 | 2011-01-27 | Ferrosan Medical Devices A/S | Haemostatic composition comprising hyaluronic acid |
JP5047797B2 (en) * | 2004-09-30 | 2012-10-10 | コヴァロン・テクノロジーズ・インコーポレーテッド | Non-adhesive elastic gelatin matrix |
US9114194B2 (en) | 2006-05-12 | 2015-08-25 | W. L. Gore & Associates, Inc. | Immobilized biologically active entities having high biological activity following mechanical manipulation |
US8496953B2 (en) | 2006-05-12 | 2013-07-30 | W. L. Gore & Associates, Inc. | Immobilized biologically active entities having a high degree of biological activity following sterilization |
US20080095830A1 (en) * | 2006-10-20 | 2008-04-24 | Van Holten Robert W | Method for making a dressing |
US20080311172A1 (en) | 2007-04-25 | 2008-12-18 | Schapira Jay N | Programmed-release, nanostructured biological construct |
US20090087569A1 (en) * | 2007-09-27 | 2009-04-02 | Fenchem Enterprises Ltd. | Methods for Preparing Highly Stable Hyaluronic Acid |
-
2003
- 2003-12-11 CA CA002509914A patent/CA2509914A1/en not_active Abandoned
- 2003-12-11 WO PCT/DK2003/000855 patent/WO2004053051A2/en active Application Filing
- 2003-12-11 AU AU2003302906A patent/AU2003302906B2/en not_active Ceased
- 2003-12-11 EP EP03812570A patent/EP1573295A2/en not_active Withdrawn
- 2003-12-11 MX MXPA05006193A patent/MXPA05006193A/en unknown
- 2003-12-11 BR BR0317237-6A patent/BR0317237A/en not_active IP Right Cessation
- 2003-12-11 PL PL377477A patent/PL377477A1/en not_active Application Discontinuation
- 2003-12-11 CN CN200380108960XA patent/CN1739017B/en not_active Expired - Fee Related
- 2003-12-11 US US10/538,918 patent/US7955288B2/en not_active Expired - Fee Related
- 2003-12-11 JP JP2004557825A patent/JP2006509502A/en active Pending
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2465357A (en) * | 1944-08-14 | 1949-03-29 | Upjohn Co | Therapeutic sponge and method of making |
GB697603A (en) * | 1948-10-06 | 1953-09-23 | Sydney Arthur Gladstone | Improvements in or relating to method of and devices for obtaining tissue from a tumour carried by a patient |
US3224434A (en) * | 1962-11-06 | 1965-12-21 | Waldemar Medical Res Foundatio | Cell collector |
US3815580A (en) * | 1972-08-31 | 1974-06-11 | C Oster | Apparatus for and method of collecting and preserving cytologic samples |
US4098728A (en) * | 1976-01-02 | 1978-07-04 | Solomon Rosenblatt | Medical surgical sponge and method of making same |
US4492305A (en) * | 1983-07-08 | 1985-01-08 | Marion Laboratories, Inc. | Package for collecting cultures |
EP0156649A2 (en) * | 1984-03-29 | 1985-10-02 | Minnesota Mining And Manufacturing Company | Sorbent sheet material |
US4997753A (en) * | 1985-04-04 | 1991-03-05 | Verax Corporation | Weighted collagen microsponge for immobilizing bioactive material |
US6261596B1 (en) * | 1993-04-02 | 2001-07-17 | Anticancer, Inc. | Method to provide for production of hair coloring pigments in hair follicles |
US5462860A (en) * | 1994-06-06 | 1995-10-31 | Minnesota Mining And Manufacturing Company | Conditioned culture medium for rapid growth and detection of microbes |
EP0702081A2 (en) * | 1994-09-19 | 1996-03-20 | Gunze Limited | Matrix for tissue culture, method for culturing tissue, method for fixing cultured tissue and artificial skin fixed |
US6045570A (en) * | 1997-02-11 | 2000-04-04 | Biointerventional Corporation | Biological sealant mixture and system for use in percutaneous occlusion of puncture sites and tracts in the human body and method |
WO1998043092A1 (en) * | 1997-03-24 | 1998-10-01 | Baystate Medical Center | Method for determining the presence of mutated brca protein |
US5939259A (en) * | 1997-04-09 | 1999-08-17 | Schleicher & Schuell, Inc. | Methods and devices for collecting and storing clinical samples for genetic analysis |
WO1999012032A1 (en) * | 1997-09-04 | 1999-03-11 | Pharmacia & Upjohn Company | A method for the evaluation of antiviral drugs |
US20020010482A1 (en) * | 1997-10-03 | 2002-01-24 | Watt Paul W. | Biopolymer sponge tubes, surgical staplers and methods of use thereof |
US20010041913A1 (en) * | 1998-05-01 | 2001-11-15 | Cragg Andrew H. | Device and method for facilitating hemostasis of a biopsy tract |
WO2001034206A2 (en) * | 1999-11-09 | 2001-05-17 | Cmic Co., Ltd. | Nucleic acid-containing complex |
Non-Patent Citations (2)
Title |
---|
QUINTAVALLA J ET AL: "Fluorescently labeled mesenchymal stem cells (MSCs) maintain multilineage potential and can be detected following implantation into articular cartilage defects" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 23, no. 1, 1 January 2002 (2002-01-01), pages 109-119, XP004322626 ISSN: 0142-9612 * |
SPENCE A M ET AL: "CEREBELLAR CAPILLARY HEMANGIOBLASTOMA: ITS HISTOGENESIS STUDIED BY ORGAN CULTURE AND ELECTRON MICROSCOPY" CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 35, no. 2, 1975, pages 326-341, XP009007586 ISSN: 0008-543X * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
WO2004081514A2 (en) * | 2003-03-12 | 2004-09-23 | Charite - Universitätsmedizin Berlin | Device and method for in vivo cell transfer |
WO2004081514A3 (en) * | 2003-03-12 | 2004-11-18 | Charite Universitaetsmedizin | Device and method for in vivo cell transfer |
WO2008080932A1 (en) * | 2006-12-29 | 2008-07-10 | Preanalytix Gmbh | Device for collecting and triggered release of a biological sample |
AU2007341282B2 (en) * | 2006-12-29 | 2012-09-20 | Preanalytix Gmbh | Device for collecting and triggered release of a biological sample |
US8911680B2 (en) | 2006-12-29 | 2014-12-16 | Preanalytix Gmbh | Device for collecting and triggered release of a biological sample |
US8628953B2 (en) | 2007-11-29 | 2014-01-14 | Hitachi Plant Technologies, Ltd. | Capturing carrier, capturing device, analysis system using the same, and method for capturing and testing microorganisms |
WO2009113944A1 (en) * | 2008-03-12 | 2009-09-17 | Hector Roldan | Sampling kit |
FR2949477A1 (en) * | 2009-09-03 | 2011-03-04 | Millipore Corp | METHOD AND DEVICE FOR SAMPLING SURFACE ANALYSIS |
EP2292730A1 (en) * | 2009-09-03 | 2011-03-09 | Millipore Corporation | Sampling method and device for the analysis of a surface |
US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
US10799611B2 (en) | 2012-06-12 | 2020-10-13 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US9999703B2 (en) | 2012-06-12 | 2018-06-19 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US10595837B2 (en) | 2013-06-21 | 2020-03-24 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US11103616B2 (en) | 2013-12-11 | 2021-08-31 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
Also Published As
Publication number | Publication date |
---|---|
CN1739017B (en) | 2011-04-06 |
MXPA05006193A (en) | 2005-12-05 |
CA2509914A1 (en) | 2004-06-24 |
EP1573295A2 (en) | 2005-09-14 |
AU2003302906B2 (en) | 2009-04-02 |
JP2006509502A (en) | 2006-03-23 |
CN1739017A (en) | 2006-02-22 |
US20060115805A1 (en) | 2006-06-01 |
WO2004053051A3 (en) | 2005-03-10 |
PL377477A1 (en) | 2006-02-06 |
US7955288B2 (en) | 2011-06-07 |
AU2003302906A1 (en) | 2004-06-30 |
BR0317237A (en) | 2005-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7955288B2 (en) | Gelatine-based materials as swabs | |
JP5525516B2 (en) | Sampling device and method of use | |
JP6033914B2 (en) | Environmental sampling articles and methods | |
US9359600B2 (en) | Biologic sample collection devices and methods of production and use thereof | |
AU736154B2 (en) | Device and methods for determination of analyte in a solution | |
US20090030341A1 (en) | Sample release system | |
US20110256531A1 (en) | Biodetection articles | |
PL189724B1 (en) | Method of detecting presence and determining content of impurities and apparatus therefor 329009 | |
EP2833794B1 (en) | Fluid sampling device and method for sampling | |
JP2006509502A5 (en) | ||
JP2010519507A (en) | Controlled transfer biological sampling device and method of using the device | |
US9708600B2 (en) | Biologic sample collection devices and methods of production and use thereof | |
Chai et al. | Environmental sampling of hospital surfaces: assessing methodological quality. | |
US20070196817A1 (en) | Sampling Device | |
JP2022524637A (en) | New sampling method for long-term monitoring of microorganisms | |
CN204897907U (en) | Hinder fungus nature test device | |
CN214074429U (en) | Chemical disinfection effect evaluation kit | |
WO2022224965A1 (en) | Specimen retention card and specimen inspection method using same | |
JPH1189592A (en) | Mensuration of atp of microorganisms | |
JP2000262271A (en) | Culture unit | |
CN109897883A (en) | Application of the nitric oxide releasing polymer in detection Escherichia coli | |
CN113308511A (en) | Method for rapidly detecting antibacterial property of glass surface | |
JP2000262269A (en) | Culture unit | |
CN105132272A (en) | Bacterium resistance test device and test method | |
UA42934C2 (en) | Method for diagnosing endotoxicosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/006193 Country of ref document: MX Ref document number: 377477 Country of ref document: PL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2509914 Country of ref document: CA Ref document number: 2004557825 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003302906 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2986/DELNP/2005 Country of ref document: IN |
|
REEP | Request for entry into the european phase |
Ref document number: 2003812570 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003812570 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A8960X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003812570 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0317237 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2006115805 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10538918 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10538918 Country of ref document: US |